Compare Aehr Test Systems (AEHR) vs Axogen Inc (AXGN) Price & Performance

AEHR Test Systems (AEHR) surged 25.02% to $132.77, driven by strong earnings beats and a $22 million follow-on order for AI processor wafer-level burn-in systems (Accesswire, August 12, 2026). The stock exhibits bullish technical signals with support at $112 and resistance at $129, though RSI suggests overbought conditions. Revenue reached $58.97 million in 2025, but net income remained negative at -$3.91 million, reflecting high growth investments.

Outlook is optimistic due to AI and silicon photonics demand, with FY27 revenue growth projected at 160–200% (Seeking Alpha, July 18, 2026). Risks include customer concentration and negative cash flow. Analysts are mixed (33% buy, 67% hold), highlighting valuation concerns at a P/S of 71.87. Upside potential exists if execution aligns with backlog growth.

AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.

The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.